News and Press Releases
Press releases
Patient Six Cancer-Free Twelve Months After Single Anti-Cancer Treatment
Results of Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) Clinical Study Demonstrate a 66% Complete Response (“CR”) at the Therapeut...
0Theralase’s Phase IB Clinical Study to be Presented at the 17th International Photodynamic Association World Congress
Toronto, Ontario – March 26, 2019 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical sta...
0Theralase® Granted United States Patent to Destroy Cancer Cells with X-Ray Activated Photo Dynamic Compounds
Toronto, Ontario – March 4, 2019 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical sta...
0Theralase® Achieves Third Place in the Clean Technology and Life Sciences Category on the 2019 TSX Venture 50
Toronto, Ontario – February 28, 2019 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical...
0Theralase® Announces Appointment of New Chief Executive Officers
Toronto, Ontario – February 25, 2019 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical...
0Theralase® Patient Five Cancer-Free Twelve Months After Single Anti-Cancer Treatment
Toronto, Ontario – January 31, 2019 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical s...
0Theralase® Patient Six Cancer-Free at Nine Months After Single Anti-Cancer Treatment
Toronto, Ontario – January 30, 2019 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical s...
0Theralase® Completes $1.4 M Private Placement Equity Financing
Toronto, Ontario – January 9, 2019 Theralase Technologies Inc. (“Theralase®” or “Company”) (TSXV: TLT) (OTCQB: TLTFF) is pleased to anno...
0Health Canada Grants ITA Approval to Commence Phase II Clinical Study
Toronto, Ontario – December 10, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”)(TSXV: TLT) (OTCQB: TLTFF), a clinical s...
0Theralase’s Rutherrin® Photo Dynamic Therapy Induces Immune Response to Destroy Human Brain Cancer Cells
Rutherrin® mediated Photo Dynamic Therapy improves cancer specific immune responses by switching the so called “Don’t eat me” signal that ca...
0in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.